DEPO - Depomed, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Hedge Fund Governors Lane Is Betting On A Seth Klarman Favorite
    Insider Monkey

    Hedge Fund Governors Lane Is Betting On A Seth Klarman Favorite

    “Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]

  • Associated Press

    Depomed: 2Q Earnings Snapshot

    The Newark, California-based company said it had a loss of 33 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 19 cents per share. The results exceeded Wall Street ...

  • ACCESSWIRE

    Depomed, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Depomed, Inc. (NASDAQ: DEPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern Time. To ...

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: OPKO Health and Depomed

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...

  • ACCESSWIRE

    Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

    Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • ACCESSWIRE

    Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

    Stock Research Monitor: ZGNX, DEPO, and DRRX LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • Depomed Inc (NASDAQ:DEPO) Is Trading At A 26% Discount
    Simply Wall St.

    Depomed Inc (NASDAQ:DEPO) Is Trading At A 26% Discount

    In this article I am going to calculate the intrinsic value of Depomed Inc (NASDAQ:DEPO) using the discounted cash flows (DCF) model. Anyone interested in learning a bit more aboutRead More...

  • Why Depomed Inc.'s Shares Soared 23.2% Higher
    Motley Fool

    Why Depomed Inc.'s Shares Soared 23.2% Higher

    The company rewarded investors with good news today.

  • Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?
    Simply Wall St.

    Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?

    Analyzing Depomed Inc’s (NASDAQ:DEPO) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...

  • When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?
    Simply Wall St.

    When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?

    Depomed Inc’s (NASDAQ:DEPO): Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States.Read More...

  • CNBC

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • CNBC

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)?
    Simply Wall St.

    Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)?

    Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. Depomed’s insiders haveRead More...

  • This Biotech Flirts With Breakout Amid Battle With Opioid Makers
    Investor's Business Daily

    This Biotech Flirts With Breakout Amid Battle With Opioid Makers

    Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.

  • Exploring Depomed’s Financial Performance Today
    Market Realist

    Exploring Depomed’s Financial Performance Today

    In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.

  • Depomed versus Peers in March 2018: Analyst Ratings
    Market Realist

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.

  • Behind Depomed’s Business Strategy
    Market Realist

    Behind Depomed’s Business Strategy

    Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.

  • Inside Depomed’s Portfolio: The Key Drugs
    Market Realist

    Inside Depomed’s Portfolio: The Key Drugs

    Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.

  • Here's Why Depomed Inc Fell as Much as 13.8% Today
    Motley Fool

    Here's Why Depomed Inc Fell as Much as 13.8% Today

    The company announced full-year 2017 earnings yesterday after the market closed.

  • Benzinga

    The Week Ahead In Biotech: Earnings, PDUFA Dates And More

    Volatility is the name of the game in profitable trading, and it's all the more relavant in the biotech space, which is subject to many make-or-break catalytic events . This apart, usual market-moving ...

  • Should You Buy Depomed Inc (NASDAQ:DEPO)?
    Simply Wall St.

    Should You Buy Depomed Inc (NASDAQ:DEPO)?

    Depomed Inc (NASDAQ:DEPO), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $8.67Read More...

  • TheStreet.com

    Opioid Litigants Get Boost From Senate Report

    A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

  • Reuters

    Opioid makers paid millions to advocacy groups - U.S. Senate report

    The report, released by Democratic Senator Claire McCaskill, said groups who received the donations aligned themselves with industry goals and may have played a role in an epidemic that in 2016 led to 42,000 opioid overdose deaths. The report released by McCaskill, the U.S. Senate Homeland Security and Governmental Affairs Committee's ranking Democrat, said the groups issued guidance promoting opioids for chronic pain and lobbied against laws to curb their use. Purdue Pharma, which on Saturday announced it would stop promoting opioids to doctors, was the biggest donor, giving $4.15 million to 12 groups from 2012 to 2017, the report said.